EP0994717A4 - Behandlung von autoimmunerkrankungen anhand einer toleranzerhoehung bewirkt durch die kombination mit methotrexat - Google Patents

Behandlung von autoimmunerkrankungen anhand einer toleranzerhoehung bewirkt durch die kombination mit methotrexat

Info

Publication number
EP0994717A4
EP0994717A4 EP98908452A EP98908452A EP0994717A4 EP 0994717 A4 EP0994717 A4 EP 0994717A4 EP 98908452 A EP98908452 A EP 98908452A EP 98908452 A EP98908452 A EP 98908452A EP 0994717 A4 EP0994717 A4 EP 0994717A4
Authority
EP
European Patent Office
Prior art keywords
tolerization
methotrexate
treatment
combination
autoimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98908452A
Other languages
English (en)
French (fr)
Other versions
EP0994717A1 (de
Inventor
Howard L Weiner
Ahmad Al-Sabbagh
Patricia A Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of EP0994717A1 publication Critical patent/EP0994717A1/de
Publication of EP0994717A4 publication Critical patent/EP0994717A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes
EP98908452A 1997-01-24 1998-01-26 Behandlung von autoimmunerkrankungen anhand einer toleranzerhoehung bewirkt durch die kombination mit methotrexat Withdrawn EP0994717A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
US36722P 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (2)

Publication Number Publication Date
EP0994717A1 EP0994717A1 (de) 2000-04-26
EP0994717A4 true EP0994717A4 (de) 2000-07-26

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98908452A Withdrawn EP0994717A4 (de) 1997-01-24 1998-01-26 Behandlung von autoimmunerkrankungen anhand einer toleranzerhoehung bewirkt durch die kombination mit methotrexat

Country Status (10)

Country Link
EP (1) EP0994717A4 (de)
JP (1) JP2001511134A (de)
KR (1) KR20000070460A (de)
AU (1) AU6648898A (de)
BR (1) BR9807112A (de)
CA (1) CA2278152A1 (de)
HU (1) HUP0001960A2 (de)
IL (1) IL131025A0 (de)
NO (1) NO993600L (de)
WO (1) WO1998032451A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2314182T3 (es) 2002-02-11 2009-03-16 Antares Pharma, Inc. Inyector intradermico.
EP1850892B2 (de) 2005-01-24 2023-04-19 Antares Pharma, Inc. Spritzenstrahlinjektor mit vorgefüllter nadel
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2007131013A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Two-stage reconstituting injector
WO2009114542A1 (en) 2008-03-10 2009-09-17 Antares Pharma, Inc. Injector safety device
EP2318075B1 (de) 2008-08-05 2019-05-22 Antares Pharma, Inc. Injektor mit mehrfachdosierung
EP2408493A1 (de) 2009-03-20 2012-01-25 Antares Pharma, Inc. System zur injektion von gefährlichen substanzen
WO2011159821A1 (en) 2010-06-16 2011-12-22 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
PT2822618T (pt) 2012-03-06 2024-03-04 Antares Pharma Inc Seringa pré-cheia com característica de força de rutura
JP6457383B2 (ja) 2012-04-06 2019-01-23 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針支援式ジェット注入投与
WO2013169804A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
ES2763633T3 (es) 2013-02-11 2020-05-29 Antares Pharma Inc Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida
ES2742046T3 (es) 2013-03-11 2020-02-12 Antares Pharma Inc Inyector de dosis con sistema de piñón
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
KR20150135339A (ko) 2013-03-13 2015-12-02 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도
EP2968309A4 (de) 2013-03-13 2016-08-31 Inflammatory Response Res Inc Verwendung von levocetirizin und montelukast bei der behandlung von vaskulitis
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004049A1 (en) * 1990-09-06 1992-03-19 Rijksuniversiteit Te Utrecht Inhibitor of lymphocyte response and immune-related disease
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases
EP0666080A1 (de) * 1987-06-24 1995-08-09 Brigham & Women's Hospital Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
WO1996040235A1 (en) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t cells
WO1996041644A1 (fr) * 1995-06-13 1996-12-27 Nippon Meat Packers, Inc. Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666080A1 (de) * 1987-06-24 1995-08-09 Brigham & Women's Hospital Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
WO1992004049A1 (en) * 1990-09-06 1992-03-19 Rijksuniversiteit Te Utrecht Inhibitor of lymphocyte response and immune-related disease
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases
WO1996040235A1 (en) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t cells
WO1996041644A1 (fr) * 1995-06-13 1996-12-27 Nippon Meat Packers, Inc. Medicament a administration par voie orale, contre la polyarthrite rhumatoide et aliment actif

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AL-SABBAGH, A.M., ET AL.: "Combination of oral antigens with oral methotrexate enhances suppression of autoimmune disease", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1(PART 2), Abs. 99, January 1997 (1997-01-01), pages s24, XP000909440 *
See also references of WO9832451A1 *

Also Published As

Publication number Publication date
BR9807112A (pt) 2001-09-18
KR20000070460A (ko) 2000-11-25
AU6648898A (en) 1998-08-18
NO993600L (no) 1999-09-23
EP0994717A1 (de) 2000-04-26
NO993600D0 (no) 1999-07-23
HUP0001960A2 (hu) 2000-10-28
JP2001511134A (ja) 2001-08-07
WO1998032451A1 (en) 1998-07-30
IL131025A0 (en) 2001-01-28
CA2278152A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
EP1024701A4 (de) Verfahren und mittel zur behandlung von autoimmunkrankheiten unter verwendung von hitzeschockproteinen
ZA9710339B (en) Xanthines and their therapeutic use
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
IL159785A0 (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
EP0924983A4 (de) S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
EP0966386A4 (de) Vom menschen fortbewegtes fahrzeug
IL144981A0 (en) Treatment of autoimmune disease
HUP0102142A3 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
HUP0001276A2 (en) Illuminating body for swimming pools and similar
HK1026096A1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL113303A0 (en) Treatment of autoimmune disease using oral tolerization and/or type I interferon
HU9602751D0 (en) Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
EP0797440A4 (de) Die behandlung von autoimmunkrankheiten mit hilfe von 2-aminopurinderivaten
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
GB9705200D0 (en) Well treatment with particles
EP1073459A4 (de) Zusammensetzungen und methoden zur tolerierung in immunkomplex-vermittelten krankheitsverläufen
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
AU7262800A (en) Diagnostic and therapeutic methods in autoimmune disease
EP1020517A4 (de) Ein aus menschlichen chondrozyten abstammendes gen
IL132845A0 (en) Non-myeloablative tolerogenic treatment
GB9706857D0 (en) Car boot seat and table

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000614

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/505 A, 7A 61K 39/00 B, 7A 61P 37/00 B, 7A 61K 39/00 J, 7A 61K 31:505 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000801